These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 31896291)

  • 1. Neuromyelitis Optica Spectrum Disorder and Anti-Aquaporin 4 Channel Immunoglobulin in an Australian Pediatric Demyelination Cohort.
    Dahan A; Brilot F; Leventer R; Kornberg AJ; Dale RC; Yiu EM
    J Child Neurol; 2020 Mar; 35(4):291-296. PubMed ID: 31896291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients.
    Hamid SHM; Whittam D; Mutch K; Linaker S; Solomon T; Das K; Bhojak M; Jacob A
    J Neurol; 2017 Oct; 264(10):2088-2094. PubMed ID: 28840314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
    van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
    Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
    Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
    Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
    Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
    J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
    Marignier R; Pittock SJ; Paul F; Kim HJ; Bennett JL; Weinshenker BG; Wingerchuk DM; Green AJ; Fujihara K; Cutter G; Aktas O; Hartung HP; Drappa J; Ratchford JN; She D; Smith M; Rees W; Cimbora D; Katz E; Cree BAC;
    Mult Scler Relat Disord; 2022 Jan; 57():103356. PubMed ID: 35158465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease.
    Lechner C; Baumann M; Hennes EM; Schanda K; Marquard K; Karenfort M; Leiz S; Pohl D; Venkateswaran S; Pritsch M; Koch J; Schimmel M; Häusler M; Klein A; Blaschek A; Thiels C; Lücke T; Gruber-Sedlmayr U; Kornek B; Hahn A; Leypoldt F; Sandrieser T; Gallwitz H; Stoffels J; Korenke C; Reindl M; Rostásy K
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):897-905. PubMed ID: 26645082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparison of Pediatric- and Adult-Onset Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder: A Review of Clinical and Radiographic Characteristics.
    Tarhan B; Rempe T; Rahman S; Rodriguez E; Sladky J; Tuna IS; Rees J
    J Child Neurol; 2022 Aug; 37(8-9):727-737. PubMed ID: 35673711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
    Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T
    J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
    Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008‒2018: A nationwide, population-based cohort study.
    Boesen MS; Jensen PEH; Born AP; Magyari M; Nilsson AC; Hoei-Hansen C; Blinkenberg M; Sellebjerg F
    Mult Scler Relat Disord; 2019 Aug; 33():162-167. PubMed ID: 31276927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
    Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
    Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody.
    Akaishi T; Fujimori J; Takahashi T; Misu T; Takai Y; Nishiyama S; Kaneko K; Ogawa R; Abe M; Ishii T; Aoki M; Fujihara K; Nakashima I
    J Neuroimmunol; 2020 Dec; 349():577431. PubMed ID: 33147540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
    Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K
    J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
    Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
    Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric neuromyelitis optica spectrum disorders in Portugal: A multicentre retrospective study.
    Martins C; Moura J; Figueiroa S; Garrido C; Martins J; Samões R; Guimarães J; Melo C; Sousa R; Palavra F; Ferreira J; da Silva AM; Sá MJ; Santos E
    Mult Scler Relat Disord; 2022 Mar; 59():103531. PubMed ID: 35078127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
    Alves Do Rego C; Collongues N
    Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.